Qiagen Says Expanded PCR IP Portfolio Will Boost Hardware and Consumables Sales, Drive Entry into IVD Market

New IP agreements with Roche and Idaho Technology not only allow the firm to sell its Rotor-Gene Q thermal cycler and reagents for both research and diagnostic applications, but also extend to high-resolution melting curve analysis technology — a key component in the company's strategy for increasing its foothold in the PCR market. The company's acquisition of DxS has also helped expand its PCR offerings for molecular diagnostics.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.